Review Article
Therapeutic Activity of Lenalidomide in Mantle Cell Lymphoma and Indolent Non-Hodgkin’s Lymphomas
Table 6
Ongoing lenalidomide-based regime trials.
| Name | Phase | Age | Histology | Drugs | Status |
| NCT01415752 | II | >60 ys | Untreated MCL | | Ongoing and recruiting | NCT01316523 | II | >18 ys | Untreated indolent NHL | RL | Ongoing and recruiting | NCT00695786 | II | >18 ys | Untreated indolent NHL | RL | Ongoing and recruiting | FIL R2-B | II | >18 ys | Untreated indolent NHL | RBL | Ongoing and recruiting |
|
|
RBV: rituximab, bendamustine, bortezomib; RL: rituximab, lenalidomide; RBL: rituximab, bendamustine, lenalidomide.
|